Qingsong Liu

发表

Systematic identification of genomic markers of drug sensitivity in cancer cells

S. Ramaswamy, M. Stratton, P. Futreal, 2012, Nature.

A Landscape of Pharmacogenomic Interactions in Cancer

Emanuel J. V. Gonçalves, M. Stratton, G. Bignell, 2016, Cell.

Sustained Akt Activity Is Required to Maintain Cell Viability in Seborrheic Keratosis, a Benign Epithelial Tumor.

Sam W. Lee, N. Gray, Qingsong Liu, 2016, The Journal of investigative dermatology.

HDAC2 Selectively Regulates FOXO3a-Mediated Gene Transcription during Oxidative Stress-Induced Neuronal Cell Death

Qingsong Liu, Zengqiang Yuan, Siqi Zhao, 2015, The Journal of Neuroscience.

Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.

P. Bourne, Qingsong Liu, S. Bliven, 2017, Journal of medicinal chemistry.

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

S. Knapp, N. Gray, Qingsong Liu, 2014, ACS chemical biology.

Anti-HCV drugs in the pipeline.

Qingsong Liu, Priscilla L. Yang, Kai Lin, 2011, Current opinion in virology.

Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2019, Journal of medicinal chemistry.

Sub-molecular features of single proteins in solution resolved with scanning tunneling microscopy

Qingsong Liu, Q. Lu, Yubin Hou, 2016, Nano Research.

Crystal Structure of the GRAS Domain of SCARECROW-LIKE7 in Oryza sativa

Qingsong Liu, Yunkun Wu, Zheng Zhao, 2016, Plant Cell.

Moderate and strong static magnetic fields directly affect EGFR kinase domain orientation to inhibit cancer cell proliferation

Qingsong Liu, Guohui Li, Q. Lu, 2016, Oncotarget.

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity

Qingsong Liu, Xianming Deng, G. Liang, 2018, Nature Communications.

Nanocrystal-loaded liposome for targeted delivery of poorly water-soluble antitumor drugs with high drug loading and stability towards efficient cancer therapy.

Qingsong Liu, Xiaofei Liang, Q. Liu, 2021, International journal of pharmaceutics.

Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.

D. Sabatini, N. Gray, Qingsong Liu, 2010, Journal of medicinal chemistry.

Interleukin-6 Secretion by Astrocytes Is Dynamically Regulated by PI3K-mTOR-Calcium Signaling

N. Gray, Qingsong Liu, L. Olson, 2014, PloS one.

STK16 regulates actin dynamics to control Golgi organization and cell cycle

Qingsong Liu, Xingxing Yang, Wen-chao Wang, 2017, Scientific Reports.

Discovery of 1-( 4-( 4-Propionylpiperazin-1-yl )-3-( trifluoromethyl ) phenyl )-9-( quinolin-3-yl ) benzo [ h ] [ 1 , 6 ] naphthyridin-2 ( 1 H )-one as a Highly Potent

N. Gray, Qingsong Liu, W. Hur, 2014 .

Selective ATP-competitive inhibitors of TOR suppress rapamycin-insensitive function of TORC2 in Saccharomyces cerevisiae.

D. Sabatini, T. Powers, M. Hall, 2012, ACS chemical biology.

Selective ATP-Competitive Inhibitors of TOR Suppress Rapamycin-Insensitive Function of TORC2 in S. cerevisiae

D. Sabatini, T. Powers, M. Hall, 2012 .

Development of ATP-competitive mTOR inhibitors.

D. Sabatini, N. Gray, Qingsong Liu, 2012, Methods in molecular biology.

Rediscovery of Traditional Plant Medicine: An Underestimated Anticancer Drug of Chelerythrine

Qingsong Liu, Xiao Ma, Y. Qi, 2022, Frontiers in Pharmacology.

Resource A Landscape of Pharmacogenomic Interactions in Cancer Graphical Abstract Highlights

Emanuel J. V. Gonçalves, M. Stratton, G. Bignell, 2016 .

Abstract 2: FGFR3 as a therapeutic target in squamous cell lung carcinoma

A. Sivachenko, G. Getz, M. Meyerson, 2012 .

Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.

Qingsong Liu, Huibin Zhang, Jinpei Zhou, 2017, Bioorganic chemistry.

An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia.

Qingsong Liu, Xiaofei Liang, Junqing Wang, 2020, Nanomedicine : nanotechnology, biology, and medicine.

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase

N. Gray, Qingsong Liu, Xianming Deng, 2015, PloS one.

Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2017, Journal of medicinal chemistry.

Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.

N. Gray, Qingsong Liu, W. Hur, 2017, European journal of medicinal chemistry.

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.

Qingsong Liu, Xiaofei Liang, Q. Liu, 2021, Journal of medicinal chemistry.

Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma

Qingsong Liu, Q. Liu, Juan Liu, 2020, Signal Transduction and Targeted Therapy.

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia

Qingsong Liu, E. Weisberg, Xiaofei Liang, 2020, Haematologica.

Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice.

A. Tischler, Qingsong Liu, S. Guichard, 2013, Endocrinology.

Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities

Qingsong Liu, Hong Wu, Beilei Wang, 2022, MedComm.

Discovery of host‐targeted covalent inhibitors of dengue virus

N. Gray, Qingsong Liu, Yanke Liang, 2017, Antiviral research.

Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.

Qingsong Liu, X. Liu, Zhenquan Hu, 2018, European journal of medicinal chemistry.

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

N. Gray, Qingsong Liu, D. McMillin, 2014, ACS chemical biology.

Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2020, Journal of medicinal chemistry.

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*

D. Sabatini, N. Gray, Qingsong Liu, 2009, Journal of Biological Chemistry.

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model

N. Gray, Qingsong Liu, Wei Wei, 2017, Scientific Reports.

An Unusual Benzoisoquinoline-9-one Derivative and Other Related Compounds with Antiproliferative Activity from Hawaiian Endophytic Fungus Peyronellaea sp. FT431

Ariel M. Sarotti, J. Turkson, Qingsong Liu, 2019, Molecules.

Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2

N. Gray, Qingsong Liu, Xianming Deng, 2011, Nature chemical biology.

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).

Qingsong Liu, Zhenquan Hu, Cheng Chen, 2021, European journal of pharmacology.

Ammonia Induces Autophagy through Dopamine Receptor D3 and MTOR

Qingsong Liu, Xiaofei Liang, U. Eggert, 2016, PloS one.

Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.

Qingsong Liu, Zhenquan Hu, Q. Liu, 2018, European journal of medicinal chemistry.

Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.

Qingsong Liu, C. Yun, Zhenquan Hu, 2018, European journal of medicinal chemistry.

Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice

S. Hunt, Qingsong Liu, B. Lumb, 2011, PAIN.

Mammalian Target of Rapamycin ( mTOR ) Inhibitor for Treatment of Cancer

D. Sabatini, N. Gray, Qingsong Liu, 2011 .

Developing irreversible inhibitors of the protein kinase cysteinome.

Nathanael S Gray, Qingsong Liu, Zheng Zhao, 2013, Chemistry & biology.

Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2017, European journal of medicinal chemistry.

Natural products as kinase inhibitors.

Qingsong Liu, Jing Liu, Junfeng Wang, 2012, Natural product reports.

Salviachinensines A-F, Antiproliferative Phenolic Derivatives from the Chinese Medicinal Plant Salvia chinensis.

Qingsong Liu, Zhenquan Hu, S. Cao, 2018, Journal of natural products.

Two new tricycloalternarenes from Hawaiian endophytic fungus Didymella sp. FT433

Qingsong Liu, Zhenquan Hu, S. Cao, 2018, Tetrahedron Letters.

Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.

Chandra Sekhar Pedamallu, Gad Getz, Kwok-Kin Wong, 2013, Cancer research.

An overview of kinase downregulators and recent advances in discovery approaches

Qingsong Liu, Hai-zhen Wang, Hong Wu, 2021, Signal Transduction and Targeted Therapy.

Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences

C. Liang, Liangdan Sun, Qingsong Liu, 2020, Molecular Biomedicine.

mTOR Mediated Anti-Cancer Drug Discovery.

D. Sabatini, N. Gray, Qingsong Liu, 2009, Drug discovery today. Therapeutic strategies.

Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.

S. Elledge, D. Sabatini, M. Niepel, 2013, Cancer research.

Characterization of Torin 2 , an ATP-Competitive Inhibitor of mTOR , ATM , and ATR Citation

S. Elledge, D. Sabatini, M. Niepel, 2013 .

ATM , and ATR Characterization of Torin 2 , an ATP-Competitive Inhibitor of mTOR

S. Elledge, D. Sabatini, M. Niepel, 2013 .

mTOR , ATM and ATR Characterization of Torin 2 , an ATP-competitive inhibitor of

S. Elledge, D. Sabatini, M. Niepel, 2013 .

Therapeutics , Targets , and Chemical Biology Characterization of Torin 2 , an ATP-Competitive Inhibitor of mTOR , ATM , and ATR

S. Elledge, D. Sabatini, M. Niepel, 2013 .

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

Bandana Sharma, Wenchao Wang, Nathanael S Gray, 2012, Cancer cell.

The tumor suppressor role of miR-155-5p in gastric cancer.

Qingsong Liu, Jun Luo, Xiaoqing Zhou, 2018, Oncology letters.

Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.

N. Gray, Qingsong Liu, C. Benes, 2012, Cancer discovery.

The controversial links among calorie restriction, SIRT1, and resveratrol.

Qingsong Liu, Jing Liu, Junfeng Wang, 2011, Free radical biology & medicine.

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

N. Gray, Qingsong Liu, J. Griffin, 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Qingsong Liu, Xianming Deng, Jinbo Cheng, 2017, The Journal of experimental medicine.

A simple, highly visual in vivo screen for anaplastic lymphoma kinase inhibitors.

R. Kelsh, Qingsong Liu, Frederico S. L. M. Rodrigues, 2012, ACS chemical biology.

Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2016, Journal of medicinal chemistry.

Inhibitor-Sensitive FGFR 2 and FGFR 3 Mutations in Lung Squamous Cell Carcinoma

Rachel G Liao, A. Sivachenko, G. Getz, 2013 .

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells

N. Gray, Qingsong Liu, C. Mitsiades, 2013, PloS one.

Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.

Travis J Cohoon, D. Hayes, D. Root, 2013, Cancer discovery.

Chaperones as thermodynamic sensors of drug–target interactions reveal kinase inhibitor specificities in living cells

Sandro Santagata, Susan Lindquist, Luke Whitesell, 2013, Nature Biotechnology.

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

Qingsong Liu, C. Yun, Zhenquan Hu, 2016, Oncotarget.

Discovery of 9-(6-aminopyridin-3-yl)-1-(3- (trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective and orally available mTOR inhibitor for treatment of cancer

D. Sabatini, N. Gray, Qingsong Liu, 2011 .

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

Sam W. Lee, N. Gray, Qingsong Liu, 2013, ACS chemical biology.

Discovery of a Potent and Selective DDR 1 Receptor Tyrosine Kinase Inhibitor

Sam W. Lee, N. Gray, Qingsong Liu, 2013 .

Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.

Jing Liu, Cheng Chen, Wei Wang, 2017, Journal of medicinal chemistry.

Clinical efficacy of low-dose emetine for patients with COVID-19: a real-world study

C. Liang, Liangdan Sun, Qingsong Liu, 2020, Journal of bio-X research.

Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.

Yan Liu, Feiyang Liu, Peng Gao, 2017, Cancer research.

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer

M. Meyerson, P. Hammerman, N. Gray, 2015, ACS chemical biology.

Combined inhibition of mTOR and PIKKs exploits replicative and checkpoint vulnerabilities to induce death of PI3K-activated triple-negative breast cancer cells

P. Sorger, M. Niepel, N. Gray, 2019, bioRxiv.

Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.

Qingsong Liu, Zheng Zhao, Hong Wu, 2015, Journal of medicinal chemistry.

Dynamic folding modulation generates FGF21 variant against diabetes

B. Bao, Qingsong Liu, Xiaokun Li, 2020, EMBO reports.

Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2019, Cancer letters.

Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors

Qingsong Liu, X. Liu, X. Xiao, 2019, Therapeutic advances in medical oncology.

Sodium rutin ameliorates Alzheimer’s disease–like pathology by enhancing microglial amyloid-β clearance

Qingsong Liu, Zengqiang Yuan, Jinbo Cheng, 2019, Science Advances.

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity

Qingsong Liu, Xianming Deng, G. Liang, 2018, Nature Communications.

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode

Qingsong Liu, C. Yun, Hong Wu, 2017, Oncotarget.

Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair

J. Minna, T. Pandita, Kwok-Kin Wong, 2016, Radiation Research.

Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells.

P. Sorger, M. Niepel, N. Gray, 2019, Cell systems.

Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia

Qingsong Liu, Yinsheng Wang, E. Weisberg, 2021, Signal Transduction and Targeted Therapy.

Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.

Qingsong Liu, C. Yun, Zhenquan Hu, 2017, European journal of medicinal chemistry.

Structure-Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent.

N. Gray, Qingsong Liu, Yanke Liang, 2017, ACS medicinal chemistry letters.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

A. Look, N. Gray, Qingsong Liu, 2013, ACS chemical biology.

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

N. Gray, Qingsong Liu, Jinhua Wang, 2016, OncoTarget.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.

Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R

Kwok-Kin Wong, N. Gray, Qingsong Liu, 2014, Clinical Cancer Research.

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.

N. Gray, Qingsong Liu, J. Griffin, 2015, Blood.

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.

Qingsong Liu, Cheng Chen, Ao-li Wang, 2020, Experimental cell research.

All-Trans Retinoic Acid Exerts Selective Anti-FLT3-ITD Acute myeloid leukemia Efficacy through Downregulating Chk1 Kinase.

Qingsong Liu, Zong-ru Jiang, Juan Liu, 2020, Cancer letters.

CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers

Qingsong Liu, Q. Liu, Hong Wu, 2022, Acta Pharmacologica Sinica.

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies

Qingsong Liu, J. Griffin, S. Fernandes, 2016, Oncotarget.

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances

Qingsong Liu, J. Griffin, S. Fernandes, 2016, OncoTarget.

Insights into the molecular recognition of the granuphilin C2A domain with PI(4,5)P2.

Qingsong Liu, Guohui Li, Jiahai Zhang, 2015, Chemistry and physics of lipids.

Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and Taxol.

Wenchao Wang, Wei Chen, Xinmiao Ji, 2016, Bioelectrochemistry.

Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition

Xin Hu, H. Ji, Qingsong Liu, 2019, Nature Communications.

Clavukoellians A-F, Highly Rearranged Nardosinane Sesquiterpenoids with Antiangiogenic Activity from Clavularia koellikeri.

Qingsong Liu, Zhenquan Hu, Jing Liu, 2019, Journal of natural products.

Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance

Qingsong Liu, K. Machida, Weiming Yuan, 2019, Nature Communications.

Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics*

P. Sorger, D. Sabatini, A. Look, 2012, The Journal of Biological Chemistry.

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours

Qingsong Liu, Hong Wu, Zong-ru Jiang, 2022, Molecular oncology.

Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2016, Journal of medicinal chemistry.

Sodium chloride (NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer

Qingsong Liu, T. Xue, Jiawei Shen, 2018, Cancer biology & therapy.

Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.

Nathanael S Gray, Qingsong Liu, N. Gray, 2009, Bioorganic & medicinal chemistry letters.

Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability.

D. Sabatini, N. Gray, Qingsong Liu, 2011, Bioorganic & medicinal chemistry letters.

Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding.

Qingsong Liu, Zhenquan Hu, Juan Liu, 2017, Journal of medicinal chemistry.

Discovery of a Highly Selective STK16 Kinase Inhibitor.

N. Gray, Qingsong Liu, Jinhua Wang, 2016, ACS chemical biology.

Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs).

Qingsong Liu, Yuexiang Wang, Zhenquan Hu, 2016, Journal of medicinal chemistry.

Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.

Qingsong Liu, Jian Ding, Lin-jiang Tong, 2018, Journal of medicinal chemistry.

Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance

Qingsong Liu, K. Machida, Weiming Yuan, 2019, Nature Communications.

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors

N. Gray, Qingsong Liu, W. Hur, 2012, Leukemia.

Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition

Xin Hu, H. Ji, Qingsong Liu, 2019, Nature Communications.

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model

N. Gray, Qingsong Liu, Wei Wei, 2017, Scientific Reports.

Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair

Qingsong Liu, Hong Wu, Chu Wang, 2020, Chembiochem : a European journal of chemical biology.

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*

D. Sabatini, N. Gray, Qingsong Liu, 2009, Journal of Biological Chemistry.

Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and Taxol.

Qingsong Liu, Zhiyuan Li, Wen-chao Wang, 2016, Bioelectrochemistry.

Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.

N. Gray, Qingsong Liu, C. Benes, 2017, Cancer research.

A simple, highly visual in vivo screen for anaplastic lymphoma kinase inhibitors.

R. Kelsh, Qingsong Liu, Frederico S. L. M. Rodrigues, 2012, ACS chemical biology.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

N. Gray, Qingsong Liu, W. Hur, 2013, ACS chemical biology.

HDAC2 Selectively Regulates FOXO3a-Mediated Gene Transcription during Oxidative Stress-Induced Neuronal Cell Death

Qingsong Liu, Zengqiang Yuan, Siqi Zhao, 2015, The Journal of Neuroscience.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2016, Journal of medicinal chemistry.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.